Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
Running, not enrolling · Phase 1 · Has a placebo group
Conditions studied: Peanut Allergy
In brief
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA.
Key facts
- Study ID
- NCT05476497
- Run by
- Allergy Therapeutics
- People needed
- 46
- Starts
- 2022-10-17
- Expected to finish
- 2026-11-01
- Last updated by the study team
- 2026-03-13
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.
Where it is running
- University of Arizona — Tucson, Arizona, United States
- University of South Florida — Tampa, Florida, United States
- University of Kansas Medical Center — Kansas City, Kansas, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Mayo Clinic — Rochester, Minnesota, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Icahn School of Medicine at Mount Sinai — New York, New York, United States
- Cleveland Clinic Foundation — Cleveland, Ohio, United States
- Trio Clinical Trials, LLC. — Houston, Texas, United States
- University of Wisconsin School of Medicine and Public Health Asthma, Allergy, and Pulmonary Clinical Research — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.